CRHBP

Across TCGA pan-cancer cohorts, CRHBP mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CRHBP data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CRHBP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRHBP expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where CRHBP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.238	0.849	.024	12	view →
GBM	OS	Quartile	All	0.962	0.804	.013	9	view →
CCRCC	DFS	Tertile	All	0.751	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CRHBP–PDAC (DFS)

Open the PDAC breakdown →